PSN821 / AstraZeneca - LARVOL DELTA

PSN821, an oral agonist of the GPR119 receptor expressed on both enteroendocrine and β-cells, induces clinically relevant reductions in energy intake in the obese and overweight after 14 days treatment (Obesity 2011) - Presentation time: Monday, October 3, 2011; Time: 9:30 AM – 1:45 PM & 3:00 PM – 6:30 PM; P=NA, N=NA; Overweight/obese volunteers taking PSN821 (250mg or 650mg) consumed fewer calories and showed greater corresponding changes in VAS scores than pbo on Day 14 at higher dose; Overweight/obese patients with T2DM taking PSN821 (250mg alone, or 250mg, 500mg on top of stable metformin therapy) consumed fewer calories (mean -6%, -8% and -40% respectively) than pbo on Day 14 at higher dose

Clinical data • Obesity

Orally administered GPR119 agonist PSN821 shows clinically significant glucose lowering and other potential cardiometabolic benefits in patients with type 2 diabetes (EASD 2011) - Presentation Time: Thursday, Sep 15, 2011, 3:00 PM - 3:15 PM; P=NA, N=NA; PSN821 was well tolerated & had showed clear evidence of both fasting & post-prandial glucose lowering, either alone or in combination with metformin; Suppression of EI at higher doses suggested weight lowering potential

Clinical data • Diabetes